Atlas Trials

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Clinical trial NCT04732871 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04732871
Sponsor
GlaxoSmithKline
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Respiratory Syncytial Virus Infections
Start date
2021-02-15
Primary completion
2022-06-06
Enrollment
1720

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.